PRODUCT CODE: ER1802-26

Fibrinogen Rabbit Polyclonal Antibody (ER1802-26)

Applications

  • WB

  • ICC

  • FC

REACTIVITY

  • Human

  • Mouse

Western blot analysis of Fibrinogen on mouse bone marrow and human kidney tissue lysates using anti-Fibrinogen antibody at 1/500 dilution.
  • Western blot analysis of Fibrinogen on mouse bone marrow and human kidney tissue lysates using anti-Fibrinogen antibody at 1/500 dilution.
  • ICC staining Fibrinogen in NIH-3T3 cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.
  • ICC staining Fibrinogen in A549 cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.
  • Flow cytometric analysis of NIH-3T3 cells with Fibrinogen antibody at 1/100 dilution (red) compared with an unlabelled control (cells without incubation with primary antibody; black). Alexa Fluor 488-conjugated goat anti-rabbit IgG was used as the secondary antibody.
Western blot analysis of Fibrinogen on mouse bone marrow and human kidney tissue lysates using anti-Fibrinogen antibody at 1/500 dilution.

Applications

  • WB

  • ICC

  • FC

REACTIVITY

  • Human

  • Mouse

SPECIFICATIONS

Product Type

Rabbit polyclonal primary

Product Name

Fibrinogen Rabbit Polyclonal Antibody (ER1802-26)

Immunogen

Native protein.

Host

Rabbit

Positive Control

Mouse bone marrow and human kidney tissue lysates, A549, NIH-3T3.

Conjugation

Unconjugated

Clonality

Polyclonal

PROPERTIES

Form

Liquid

Storage Condition

Store at +4C after thawing. Aliquot store at -20C or -80C. Avoid repeated freeze / thaw cycles.

Storage Buffer

1*PBS (pH7.4), 0.2% BSA, 50% Glycerol. Preservative: 0.05% Sodium Azide.

Concentration

1 ug/ul

PURIFICATION

Protein A purified.

MOLECULAR WEIGHT

70/55 kDa

Isotype

IgG

APPLICATION DILUTION

  • WB

  • 1:500

  • ICC

  • 1:100-1:500

  • FC

  • 1:50-1:100

TARGET

UNIPROT #

PROTEIN NAME

Fibrinogen

SYNONYMS

FGA antibody; Fib2 antibody; FIBA_HUMAN antibody; Fibrinogen A alpha polypeptide antibody; Fibrinogen alpha chain antibody; Fibrinogen B alpha polypeptide antibody; Fibrinogen beta chain antibody; Fibrinogen G alpha polypeptide antibody; Fibrinogen gamma chain antibody; fibrinogen, B beta polypeptide antibody; fibrinogen, G gamma polypeptide antibody; fibrinogen, gamma polypeptide antibody; Fibrinogen--alpha -polypeptide chain antibody; Fibrinogen--beta -polypeptide chain antibody; Fibrinogen--gamma-polypeptide chain antibody

TISSUE SPECIFICITY

Detected in blood plasma (at protein level).

POST-TRANSLATIONAL MODIFICATION

The alpha chain is normally not N-glycosylated. It is well known that heterologous expression of isolated domains can lead to adventitious protein modifications. Besides, glycosylation at Asn-686 is supported by large-scale glycoproteomics studies (PubMed:16335952 and PubMed:19159218), but the evidence is still quite tenuous. Most likely, Asn-686 is not glycosylated in the healthy human body, or only with low efficiency.; O-glycosylated.; Forms F13A-mediated cross-links between a glutamine and the epsilon-amino group of a lysine residue, forming fibronectin-fibrinogen heteropolymers.; About one-third of the alpha chains in the molecules in blood were found to be phosphorylated.; Conversion of fibrinogen to fibrin is triggered by thrombin, which cleaves fibrinopeptides A and B from alpha and beta chains, and thus exposes the N-terminal polymerization sites responsible for the formation of the soft clot. The soft clot is converted into the hard clot by factor XIIIA which catalyzes the epsilon-(gamma-glutamyl)lysine cross-linking between gamma chains (stronger) and between alpha chains (weaker) of different monomers.; Phosphorylated by FAM20C in the extracellular medium.

SUBCELLULAR LOCATION

Secreted.

FUNCTION

The plasma glycoprotein Fibrinogen is synthesized in the liver and comprises three structurally different subunits: a, b and g. Fibrinogen is important in platelet aggregation, the final step of the coagulation cascade (i.e. the formation of Fibrin) and determination of plasma viscosity and erythrocyte aggregation. It is both constitutively expressed and inducible during an acute phase reaction. Hemostasis following tissue injury deploys essential plasma procoagulants (Prothrombin and Factors X, IX, V and VIII), which are involved in a blood coagulation cascade leading to the formation of insoluble Fibrin clots and the promotion of platelet aggregation. Following vascular injury, Fibrinogen is cleaved by Thrombin to form Fibrin, which is the most abundant component of blood clots. The cleavage products of Fibrinogen regulate cell adhesion and spreading, display vasoconstrictor and chemotactic activities, and are mitogens for several cell types.